Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: Cost-effectiveness analysis

Journal of Thoracic and Cardiovascular Surgery

Volumn 126, Issue 6, 2003, Pages 1935-1942

  Ferguson, Mark K ^a   Mathisen, Douglas J ^b   Detterbeck, Frank C ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; LUNG CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; META ANALYSIS; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RISK BENEFIT ANALYSIS; THORACOSCOPY; THORACOTOMY; TREATMENT PLANNING;

EID: 0347694955     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2003.07.031     Document Type: Article

References (54)

1. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Luug Cancer. 1999;26:7-14.
2. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994; 86:673-80.
3. American Joint Committee on Cancer. AJCC staging manual. 6th ed. New York: Springer-Velag; 2002.
4. Ishida T, Tateishi M, Kaneko S, Sugimachi K. Surgical treatment of patients with nonsmall-cell lung cancer and mediastinal lymph node involvement. J Surg Oncol. 1990;43:161-6.
5. Watanabe Y, Shimizu J, Oda M, et al. Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg. 1991;51: 253-61.
6. van Klaveren RJ, Festen J, Otten HJ, Cox AL, de Graaf R, Lacquet LK. Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg. 1993;56:300-4.
7. Dalton R, Keller S. Survival following resection of clinically occult N2 non small cell lung cancer. J Cardiovasc Surg (Torino), 1994;35:13-7.
8. Goldstraw P, Mannam GC, Kaplan DK, Michail P. Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg, 1994;107:19-27.
9. Miller DL, McManus KG, Allen MS, et al. Results of surgical resection in patients with N2 non-small cell lung cancer. Ann Thorac Surg. 1994;57:1095-101.
10. De Leyn P, Schoonooghe P, Deneffe G, et al. Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease). Eur J Cardiothorac Surg. 1996;10: 649-54.
11. Nakanishi R, Osaki T, Nakanishi K, et al. Treatment strategy for patients with surgically discovered N2 stage IIIA non-small cell lung cancer. Ann Thorac Surg. 1997;64:342-8.
12. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981-9.
13. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations. Chest. 2000;118:123-8.
14. Ohta M, Tshuchiya R, Shimoyama M, et al. Adjuvant chemotherapy for completely resected stage 111 non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1993;106:703-8.
15. Debevec M, Bitenc M, Vidmar S, et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study 1988-1992. Lung Cancer. 1996;14:99-107.
16. Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group. Cancer Prev Control. 1997;1:366-78.
17. Steinbaum SS, Uretzky ID, McAdams HP, Torrington KG, Cohen AJ. Exploratory thoracotomy for nonresectable lung cancer. Chest. 1995; 107:1058-61.
18. Yashar J, Weitberg AB, Glicksman AS, Posner MR, Feng W, Wanebo HJ. Preoperative chemotherapy and radiation therapy for stage IIIa carcinoma of the lung. Ann Thorac Surg. 1992;53:445-8.
19. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992;53:992-8.
20. Reddy S, Lee MS, Bonomi P, et al. Combined modality therapy for stage III non-small cell lung carcinoma: results of treatment and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;24:17-23.
21. Burkes RL, Ginsberg RJ, Shepherd RA, et al. Induction chemotherapy with MVP (mitomycin-C + vindesine + cisplatin) for stage III (T1-2, N2, M0) unresectable non-small cell lung cancer: the Toronto experience. Lung Cancer. 1993;9:377-82.
22. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993;55:1365-73.
23. Elias AD, Skarin AT, Gonin R, et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Am J Clin Oncol. 1994;17:26-36.
24. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330: 153-8.
25. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998;21:1-6.
26. Chella A, Lucchi M, Ribechini A, et al. Pre-operative chemotherapy for stage IIIa (N2) non-small cell lung cancer. Eur J Surg Oncol. 1995;21:393-7.
27. Darrwish S, Minotti V, Crino L, et al. A phase 11 trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer. Lung Cancer. 1995;12(Suppl 1):S71-8.
28. Rice TW, Adelstein DJ, Koka A, Tefft M, Kirby TJ, Van Kirk MA. Accelerated induction therapy and resection for poor prognosis stage 111 non-small cell lung cancer. Ann Thorac Surg. 1995;60:586-92.
29. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase 11 trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg. 1995;109:473-83.
30. Mathisen DJ, Wain JC, Wright C, et al. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1996;111:123-33.
31. Elias AD, Skarin AT, Leong T, et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer. 1997;17:147-61.
32. Granone P, Margaritora S, Cesario A, Bonatti P, Galetta D, Picciocchi A. Concurrent radio-chemotherapy in N2 non small cell lung cancer: interim analysis. Eur J Cardiothorac Surg. 1997;12:366-71.
33. De Leyn P, Vansteenkiste J, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy. Eur J Cardiothorac Surg. 1999;15:608-14.
34. Ahn YC, Park K, Kim DY, et al. Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer. Acta Oncol. 2001;20:588-92.
35. Voltolini L, Luzzi L, Ghiribelli C, Paladini P, Di Bisceglie M, Gotti G. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur J Cardiothorac Surg. 2001;20:1106-12.
36. Kim DH, Lynch TJ, Mentzer SJ, et al. Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging. J Thorac Cardiovasc Surg. 1993;106:696-702.
37. Maggi G, Casadio C, Cianci R, et al. Preoperative concurrent radiation and cisplatinum continuous infusion in IIIa (N2) non small cell lung cancer. A pilot study. J Cardiovasc Surg. 1994;35:341-6.
38. Earle C, Coyle D, Smith A, Agboola O, Evans WK. The cost of radiotherapy at an Ontario regional cancer centre: a re-evaluation. Crit Rev Oncol Hematol. 1997;32:87-93.
39. Coy P, Schaafsma J, Schofield JA. The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:1025-33.
40. Evans WK, Will BP, Berthelot J-M, Earle CC. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol. 1997;15:3038-48.
41. Earle CC, Evans WK. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer. 1999;80:815-20.
42. Sacristan JA, Kennedy-Martin T, Rosell R, et al. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer. 2000;28:97-107.
43. Chen Y-M, Perng R-P, Lee Y-C, et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol. 2002;13:108-15.
44. Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax. 2002;57: 20-8.
45. Lees M, Aristides M, Maniadakis N, McKendrick J, Botwood N, Stephenson D. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics. 2002;20:325-37.
46. Zieren HU, Muller JM, Hamberger U, Pichlmaier H. Quality of life after surgical therapy of bronchogenic carcinoma. Eur J Cardiothorac Surg. 1996;10:223-7.
47. Mangione CM, Goldman L, Orav EJ, et al. Health-related quality of life after elective surgery. Measurement of longitudinal changes. J Gen Intern Med. 1997;12:686-97.
48. Handy JR Jr, Asaph JW, Skokan L, et al. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest. 2002;122:21-30.
49. Li WW, Lee TW, Lam SSY, et al. Quality of life following lung cancer resection. Video-assisted thoracic surgery vs thoracotomy. Chest. 2002;122:584-9.
50. Paul A, Marelli D, Wilson JA, Chiu RC, Mulder DS. Does the surgical trauma of "exploratory thoracotomy" affect survival of patients with bronchogenic carcinoma? Can J Surg. 1989;32:322-7.
51. Takizawa T, Terashima M, Koike T, Akamatsu H, Kurita Y, Yokoyama A. Mediastinal lymph node metastasis in patients with clinical stage I peripheral non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;113:248-52.
52. Pettitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis. 2nd ed. New York: Oxford University Press; 2000.
53. Le Chevalier T. IALT Investigators. Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2003;22:2.
54. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care. 1998; 36(Suppl 5):MS1-147.